Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
1 study found for:    22276820 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Completed Bevacizumab, Everolimus (RAD001), and Lapatinib as Neoadjuvant Chemotherapy Regimes for Primary Breast Cancer
Condition: Breast Cancer
Interventions: Drug: epirubicin - cyclophosphamide / docetaxel;   Drug: epirubicin - cyclophosphamide / docetaxel + bevacizumab;   Drug: paclitaxel;   Drug: paclitaxel + everolimus (RAD001);   Drug: epirubicin - cyclophosphamide / docetaxel + trastuzumab;   Drug: epirubicin - cyclophosphamide / docetaxel + lapatinib

Study has passed its completion date and status has not been verified in more than two years.